Sanket Agrawal is a seasoned and science-forward biopharma leader who joined 1859 as CEO in April 2023. He brings deep experience in building global organizations, driving growth and commercial strategies for novel therapeutics and diagnostics. At 1859, Sanket leads a talented, multidisciplinary team dedicated to disrupting small molecule drug discovery by powering AIML with unique proprietary empirical data, a true convergence of biology and in silico. Prior to 1859, Sanket served as CBO at Foundation Medicine, a pioneering cancer genomics company, where he led the largest biopharma business in the sector and partnered with biopharma companies to advance cancer research and therapeutics. He held various executive roles at Amgen for nearly 15 years, most recently as General Manager for KRAS, where he led the rapid development and launch of the first ever targeted therapy for KRAS-mutant non-small cell lung cancer. Sanket holds an MBA from UCLA, an MPH from the University of Liverpool, and an M.Eng. in Information Systems from the University of Toronto.